Oruka Therapeutics, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Oruka Therapeutics, Inc. (Nasdaq: ORKA) is a clinical-stage biopharmaceutical company that develops novel monoclonal antibody therapeutics targeting inflammatory and immunology indications, with a primary focus on plaque psoriasis, psoriatic arthritis, and related dermatologic conditions. The company's lead product candidates include ORKA-001, a potentially best-in-class inhibitor of the p19 subunit of interleukin-23 (IL-23p19) in Phase 1 clinical trials for moderate-to-severe plaque psoriasis and engineered with half-life extension technology for potential dosing as infrequently as once or twice per year; ORKA-002, an IL-17A/F dual inhibitor advancing toward the clinic for psoriasis, psoriatic arthritis, and other conditions with potential dosing two or three times annually; ORKA-003 targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 followed by ORKA-001 designed for rapid response and durable maintenance in plaque psoriasis. Founded in 2024 and headquartered in Menlo Park, California, Oruka Therapeutics optimizes antibody properties such as high target affinity, extended half-life, low immunogenicity, and subcutaneous administration to pursue superior efficacy, safety, and convenience over existing standards. In September 2024, the company completed a merger with ARCA biopharma, Inc., under which it became the surviving entity trading as Oruka Therapeutics, Inc. (Nasdaq: ORKA), and concurrently closed a $275 million private placement financing led by investors including Fairmount Funds, Venrock Healthcare Capital Partners, and RTW Investments to fund pipeline advancement; Oruka continues to progress ORKA-001 toward initial pharmacokinetic data and first-in-human dosing in 2025 while preparing ORKA-002 for clinical entry.
Company News
ORKA Stock Up More Than 60% in 3 Months: Here's What You Should Know
BlackRock Inc. Purchases Shares of 4,990,181 Oruka Therapeutics, Inc. $ORKA
Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer
4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026
Oruka Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Oruka Stock Is Now Up Nearly 700%. Here's What a $687,000 Insider Sale Could Mean
Oruka Therapeutics' Head of Finance Sold Over 10,000 Company Shares. What Does That Mean for Investors?
Oruka Therapeutics, Inc. (ORKA) Upgraded to Buy: What Does It Mean for the Stock?
Wall Street Analysts Believe Oruka Therapeutics, Inc. (ORKA) Could Rally 111.13%: Here's is How to Trade
An Oruka Therapeutics (ORKA) Insider Sold 105,000 Shares Worth $6.2 Million
Oruka Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Why This Biotech Fund Increased Its Oruka Therapeutics Stake Amid a Staggering 500% Rally
Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology
Oruka Therapeutics Touts “Category-Winning” ORKA-001 Data, Targets Once-Yearly Psoriasis Dosing
Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering
Oruka Therapeutics, Inc. (ORKA) Discusses Interim Results From EVERLAST-A Study of ORKA-001 in Moderate to Severe Plaque Psoriasis Transcript
Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering
Oruka Therapeutics: 'Strong Buy' On Half-Life Extended IL-23p19 Inhibitor ORKA-001
Oruka Therapeutics Stock Explodes As Psoriasis Data Shows 'Highly Compelling' Skin Clearance